subjects who got the vaccine mounted a moderate immune response to the virus sars-cov-2, which peaked 28 days after the inoculation, the researchers found.
subjects who got the vaccine mounted a moderate immune response to the virus sars-cov-2, which peaked 28 days after the inoculation, the researchers found.